Completed all preclinical studies and manufacturing to support PMN310 IND submission to U.S. Food and Drug Administration Preclinical data that further characterize ongoing programs, including PMN310, ...
CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and ...
ProMIS Neurosciences Inc., a biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases, announced progress in its clinical programs and shared insights from its ...
Zacks Investment Research on MSN
All you need to know about Promis Neurosciences (PMN) rating upgrade to buy
Promis Neurosciences (PMN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- ...
View ProMIS Neurosciences Inc. PMN stock quote prices, financial information, real-time forecasts, and company news from CNN.
ProMIS Neurosciences (NASDAQ:PMN) just reported results for the second quarter of 2024. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly ...
The filing details the company's financial position, reporting an operating loss of $16.8 million with working capital of approximately $17.0 million as of December 31, 2024. The company acknowledges ...
ProMIS Neurosciences Inc. (Nasdaq:PMN), a clinical-stage biotechnology firm specializing in treatments for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) ...
ProMIS Neurosciences Inc., a clinical-stage biotechnology firm, announced its plan to present preclinical data on novel computationally-derived vaccines targeting neurodegenerative diseases at the ...
Patient-reported outcomes are important predictors of morbidity and mortality. The validity and reliability of the Patient Reported Outcomes Measurement Information System (PROMIS) computerized ...
The event will feature leading companies and key opinion leaders in Alzheimer’s disease research, discussing the current treatment landscape, development of disease modifying therapies and symptom ...
"2024 was a transformational year for ProMIS Neurosciences as we reached a major milestone with the initiation of our 100-patient Phase 1b clinical trial for PMN310, our lead antibody candidate for AD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results